0000000000756025

AUTHOR

Felix Gerhardt

showing 3 related works from this author

Chronisch thromboembolische pulmonale Hypertonie: Empfehlungen der Kölner Konsensus Konferenz 2016

2016

The 2015 European Guidelines on Pulmonary Hypertension did not cover only pulmonary arterial hypertension (PAH), but also other significant subgroups of pulmonary hypertension (PH). In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were initiated, one of which was dedicated to the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). In ev…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentConsensus conference610 Medicine & health2700 General MedicineGeneral Medicine030204 cardiovascular system & hematologymedicine.diseasePulmonary hypertension3. Good healthPulmonary endarterectomy03 medical and health sciences0302 clinical medicinePharmacotherapy030228 respiratory systemAngioplastymedicine.arteryPulmonary arterymedicineChronic thromboembolic pulmonary hypertension10178 Clinic for PneumologyIntensive care medicinebusinessPediatric cardiologyDMW - Deutsche Medizinische Wochenschrift
researchProduct

Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism

2021

BACKGROUND Few data are available on the long-term course and predictors of quality of life (QoL) following acute pulmonary embolism (PE). RESEARCH QUESTION What are the kinetics and determinants of disease-specific and generic health-related QoL 3 and 12 months following an acute PE? STUDY DESIGN AND METHODS The Follow-up after Acute Pulmonary Embolism (FOCUS) study prospectively followed up consecutive adult patients with objectively diagnosed PE. Patients were considered for study who completed the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire at predefined visits 3 and 12 months following PE. The course of disease-specific QoL as assessed using the PEmb-QoL and the impact …

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryVisual analogue scalePatient-centered outcomesCritical Care and Intensive Care Medicinemedicine.diseasehumanitiesPulmonary embolismClinical trialQuality of lifeInterquartile rangeInternal medicineMedicineCardiology and Cardiovascular MedicinebusinessCohort studyCardiopulmonary diseaseChest
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct